Literature DB >> 2896911

Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease.

P N Durrington1, M Ishola, L Hunt, S Arrol, D Bhatnagar.   

Abstract

Middle-aged men who had had a myocardial infarction were compared with controls matched for social background, age, cigarette-smoking, blood pressure, and alcohol consumption. Serum cholesterol, triglycerides, very low density lipoprotein, low density lipoprotein, high density lipoprotein (HDL), HDL2 and HDL3 cholesterol, and serum apolipoproteins (apo) (a), AI, and B were measured. Discriminant analysis showed that the combination of these variables that best distinguished patients from controls was provided by apo AI and apo B and a knowledge of parental history of early cardiac death, the most discriminating single factor being apo B. No other variable contributed more than these. Apo (a), however, could be substituted for parental history, which had a major influence on the serum concentration of apo (a). Apo (a) concentration accounted for much of the familial predisposition to cardiac ischaemia. These findings may prove valuable in the clinical assessment of genetic susceptibility to myocardial infarction. They also support the hypothesis that serum apo (a) concentration is a genetic trait that predisposes to arterial thrombosis. Apo B emerged as the main lipoprotein determinant of coronary disease risk.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896911     DOI: 10.1016/s0140-6736(88)91895-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

1.  Lipid profile, haemostatic variables and angiographically-defined coronary artery disease: a cross-sectional study in an Irish population.

Authors:  J Galvin; M Codd; S Leavy; D Sugrue
Journal:  Ir J Med Sci       Date:  1996 Apr-Jun       Impact factor: 1.568

2.  Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery.

Authors:  J S Skinner; M Farrer; C J Albers; K Piper; H A Neil; P C Adams
Journal:  Heart       Date:  1997-08       Impact factor: 5.994

3.  Expressed hypervariable polymorphism of apolipoprotein (a).

Authors:  M I Kamboh; R E Ferrell; B A Kottke
Journal:  Am J Hum Genet       Date:  1991-11       Impact factor: 11.025

4.  The age dependency of gene expression for plasma lipids, lipoproteins, and apolipoproteins.

Authors:  H Snieder; L J van Doornen; D I Boomsma
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

Review 5.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

6.  Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

Authors:  D T Vallance; H A Staunton; A F Winder
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

7.  Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey.

Authors:  M F Laker; J P Reckless; D J Betteridge; P N Durrington; J P Miller; D P Nicholls; J Shepherd; G R Thompson
Journal:  J Clin Pathol       Date:  1992-02       Impact factor: 3.411

8.  Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction.

Authors:  A D MBewu; P N Durrington; M I Mackness; L Hunt; W H Turkie; J E Creamer
Journal:  Br Heart J       Date:  1994-04

9.  Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease.

Authors:  M Farrer; F L Game; C J Albers; H A Neil; P H Winocour; M F Laker; P C Adams; K G Alberti
Journal:  BMJ       Date:  1993-10-02

10.  The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.

Authors:  D J Rader; W Cain; K Ikewaki; G Talley; L A Zech; D Usher; H B Brewer
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.